At CES, ReliefBand Technologies, a leader in therapeutic technology has unveiled the ReliefBand an FDA cleared device for the drug-free treatment of nausea associated with motion and morning sickness. Part of a new generation of wearable technology that can treat, alleviate and help with conditions rather than just monitor and measure vitals. It will debut at retail in Q1 2016 following its successful Q4 2015 beta test.
ReliefBand’s patented technology uses accurately programmed pulses with highly specific waveform, frequency, and intensity to stimulate the median nerve on the underside of the wrist. This precise activity (technically referred to as “neuromodulation”) uses the body’s natural neural pathways to block the waves of nausea produced by the stomach. It provides a non-drug solution without any of the safety concerns or side effects of RX medications such as drowsiness, dry mouth, or potential for adverse drug interactions. A user need only slip the device onto their wrist, adjust the intensity to suit their individual needs and within minutes will be feeling themselves again.
The technology behind ReliefBand is clinically proven and has been prescribed by doctors for the treatment of morning sickness, post-operative nausea and sickness caused by therapies such as chemotherapy for nearly twenty years. The signals generated by the device travel to the body’s central nervous system and the higher emetic center of the brain.1 The signals modulate the neural pathways between the brain and the stomach, via the vagus nerve, restoring normal gastric rhythm and relieving nausea.2,3
ReliefBand has now brought this technology to a re-usable device that consumers can buy over the counter. Now indicated for both morning and motion sickness, ReliefBand is the evolution of an earlier RX product for morning sickness called PrimaBella, previously (only available with a prescription) and ReliefBand Voyager a throw away device for motion sickness. These devices were considered way ahead of their time, launched years before the term wearable tech was even coined. The all new ReliefBand features improved wearability, more advanced algorithms that better control the pulses and overall effectiveness of the device, replaceable batteries for ongoing use and multiple intensity settings.
“With 70% of women experiencing morning sickness during pregnancy and more than 60 million people suffering from motion sickness, ReliefBand is fulfilling a very large unmet need,” said Nick Spring, CEO, ReliefBand Technologies. “With wearable technology becoming widely accepted, the time is now right to bring this clinically proven technology that has been developed over decades to a device that people can buy without a prescription.”
In December 2015, ReliefBand Technologies raised $5 million in venture capital funding in a round led by PathoCapital the specialty healthcare fund headed by former Baxter Healthcare and Ovation Pharmaceuticals CEO, Bill Gantz. The investment will fuel the consumer market introduction of ReliefBand as it targets the maternity, cruise ship, pleasure-craft and travel markets.
ReliefBand Technologies will be unveiling the commercial units of the device at CES January 6-9, 2016 at the Sands Expo Center, Hall C Booth #73152
Filed Under: M2M (machine to machine)
